Abstract Heparin is a potent inhibitor of the proliferation and migration of vascular smooth muscle cells. This agent selectively inhibits the transcription of tissue-type plasminogen activator and interstitial collagenase, probably by decreasing the binding of activator protein-1 (AP-1) to phorbol ester-responsive elements in the promoters of these genes. Decreased AP-1 binding is not due to a direct inhibition by heparin, since heparinase digestion of nuclear extracts prepared from heparin-treated smooth muscle cells does not restore AP-1 binding activity. Treatment of cells with heparin suppresses the expression of Jun B, one of the components of AP-1. The major effect of heparin is at the level of posttranslational modification of Jun B. Results from pulse-chase labeling experiments show that the newly synthesized Jun B is rapidly converted to a higher-molecular-weight form and that conversion is suppressed by heparin. Evidence is presented suggesting that the heparin-inhibited event is phosphorylation of Jun B. (Circ Res. 1994;75:15-22.) Key Words * Jun B * posttranslational phosphorylation * tissue-type plasminogen activator * interstitial collagenase * activator protein-1 P roliferation and migration of vascular smooth muscle cells (SMCs) contribute to the restenosis of arteries subjected to angioplasty, and effective treatment of this disorder should regulate these responses to injury. Heparin may be an appropriate drug for this purpose because it inhibits SMC growth and migration both in vitro' 2 and in vivo.34 It is of interest to understand how heparin produces these inhibitory effects, since heparin-like glycosaminoglycans secreted by endothelial cells may be endogenous inhibitors of SMCs in vivo.56 The mechanism of heparin action is still not known, even though there is a vast literature describing its effects. Heparin has been shown to affect a number of cellular functions: it decreases the expression of oncogenes,78 it decreases the binding of different growth factors,9-11 it enhances the activity of a growth inhibitor,12 and it alters the deposition of matrix proteins.13 It is not clear whether these effects represent different pathways or whether they are related to a common pathway that is modulated by heparin. It is also not known whether heparin enters the cells and acts directly or whether it acts indirectly via secondary mediators to produce these effects.
P roliferation and migration of vascular smooth muscle cells (SMCs) contribute to the restenosis of arteries subjected to angioplasty, and effective treatment of this disorder should regulate these responses to injury. Heparin may be an appropriate drug for this purpose because it inhibits SMC growth and migration both in vitro' 2 and in vivo. 34 It is of interest to understand how heparin produces these inhibitory effects, since heparin-like glycosaminoglycans secreted by endothelial cells may be endogenous inhibitors of SMCs in vivo.56 The mechanism of heparin action is still not known, even though there is a vast literature describing its effects. Heparin has been shown to affect a number of cellular functions: it decreases the expression of oncogenes,78 it decreases the binding of different growth factors,9-11 it enhances the activity of a growth inhibitor,12 and it alters the deposition of matrix proteins.13 It is not clear whether these effects represent different pathways or whether they are related to a common pathway that is modulated by heparin. It is also not known whether heparin enters the cells and acts directly or whether it acts indirectly via secondary mediators to produce these effects.
To understand the mechanism of heparin action, we have identified a pathway that is modulated by heparin and hope to determine the molecular basis of the action of heparin by unraveling this pathway. We have previously shown that heparin selectively inhibits the expression of two proteases, tissue-type plasminogen activator (TPA) and interstitial collagenase, in an in vitro mitogenesis model using baboon SMCs.14,5 Heparin also decreases the expression of TPA in rat SMCs induced to migrate by arterial injury. 16 Further investigation has suggested that heparin inhibits the transcription of TPA and collagenase by decreasing the binding of a transacting factor, activator protein-1 (AP-1), to the phorbol ester-responsive element (TRE) ." A consensus TRE sequence is present in the promoter of collagenase gene,17 and a similar, but not identical, sequence is found in TPA. 18 The binding of AP-1 to the TRE is sufficient to activate the transcription of collagenase. 17 Hence, the inhibitory effect of heparin on TPA and collagenase may be related to its inhibitory effect on AP-1 binding.
It has been suggested that heparin decreases AP-1 binding by direct inhibition in HeLa cells. 19 We have examined this possibility in baboon SMCs and have found that digestion of the nuclear extracts with heparinase does not restore the decreased AP-1 binding. This result suggests that the decrease in AP-1 binding is not by direct inhibition. We also examine the possibility that heparin decreases AP-1 binding by inhibiting the expression of one or more proteins of the AP-1 complexes.
Materials and Methods

Materials
Heparin (isolated from porcine intestine mucosa), phorbol 12-myristate 13-acetate (PMA), heparinase (isolated from Flavobacterium heparinum), and cell culture media were obtained from Sigma Chemical Co. Recombinant heparinase was a generous gift from Dr Robert Rosenberg, MIT. Arctic shrimp alkaline phosphatase (SAP) was obtained from USB. Antibodies and blocking peptides to Jun B and c-Jun were purchased from Santa Cruz Biotechnology, Inc, and Oncogene Science. Reagents used for RNA isolation and Northern 
Results
Effect of Heparinase on AP-1 Binding
We have previously shown that PMA increases AP-1 binding in SMCs and that heparin decreases the induced AP-1 activity. To determine whether the decreased AP-1 binding was due to a direct inhibition by heparin in the extracts, nuclear extracts from SMCs were predigested with heparinase before the binding assays. Digestion with heparinase of nuclear extracts prepared from heparin-treated cells did not restore the decreased AP-1 binding (Fig 1, lane 4 versus 5) . Hence, the decreased AP-1 binding was not due to a direct inhibition by heparin. We have examined the possibility that heparinase inhibitory activity might be present in the nuclear extracts by deliberately adding exogenous (Fig 3) . The two specific bands could be blocked by a Jun B peptide (amino acid [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] , against which the antibody was made (Fig 3) . This region (amino acid 45- (Fig 4, left panel) (Fig 4, left panel) . These two bands were specific to Jun B, since they could be blocked by the Jun B peptide (data not shown). Furthermore, both bands were detected by immunoprecipitation under nondenaturing or denaturing conditions, which suggested that these two bands were not a result of coimmunoprecipitation. PMA increased the labeling of the 43-kD and 39-kD Jun B bands by 3.5±0.6-and 3.0±0.4-fold, respectively, above the serum-free control (n=9). Heparmn decreased the PMA-induced 43-kD Jun B by 61±9% (P<.005, n=9) and the 39-kD Jun B by 38±22% (P<.01, n=9) (Fig 4, left panel) . Heparin had no effect on the efficiency of immunoprecipitation of Jun B, since addition of heparin (20 ,ug/mL) directly to the assay did not affect the amount of Jun B recovered (data not shown).
The effect of heparin on c-Jun expression was determined by immunoprecipitation (Fig 4, right panel) . The antibody to c-Jun detected a 40-kD c-Jun band and a 43-kD nonspecific band. The 40-kD band is specific to c-Jun, since it could be completely eliminated by the blocking peptide (residue 73-87) (data not shown). The level of c-Jun was not significantly increased by PMA (22±17%, n=8). Heparin slightly decreased the level of c-Jun (Fig 4, right panel) .
Jun B in AP-1 Complexes
Whether heparin decreases Jun B in the AP-1 complexes was determined by supershift gel-retardation assay. The presence of Jun B in the complexes was detected by the formation of a higher-molecular-weight complex with the antibody, as indicated by a supershift band (Fig 5, lane 5) . This supershift band was specific to Jun B, as it could be eliminated by the Jun B blocking peptide (Fig 5, lane 9 versus 8) . Also, the Jun B supershift was not a result of artifactual shift due to the addition of excess antibody, since this supershift band was not observed in the presence of an irrevelant antibody such as NF-kB (data not shown). PMA in- heparin suppressed the induction by -70% (Fig 5, lane  5 versus 6 ). These results indicate that the decreased Jun B expression by heparin (Fig 4, left panel) Results from pulse-chase experiments showed that the 39-kD Jun B was the precursor to the 43-kD Jun B. The 39-kD Jun B was the predominant species after a brief labeling (Fig 6a, 0 minutes) , and it rapidly converted to the 43-kD form during the chase (Fig 6a) . This conversion was illustrated by the 43-kD-to-39-kD ratio at various periods. In PMA-stimulated cells, the ratio increased from 0.8 to 3.1 after 80 minutes of chase (Fig  6b) . The 39-kD Jun B was the predominant species after brief labeling (Fig 6a, 0 minutes) , whereas the 43-kD Jun B was the predominant species after continuous labeling (Fig 3) . This difference was due to the rapid conversion of the newly synthesized 39-kD Jun B to the 43-kD form.
Heparin slowed the conversion of the 39-kD Jun B to the 43-kD Jun B (Fig 6a) . Results from three experiments showed that heparin consistently decreased the apparent conversion of the 39-kD Jun B to the 43-kD Jun B, as demonstrated by a lower ratio at a range of time points (Fig 6b) . The decreased conversion in the presence of heparin also was reflected in the longer half-life of the 39-kD Jun B, which was estimated to be 71 versus 56 minutes in PMA-stimulated cells. In this particular experiment, heparin appeared to decrease the amount of Jun B synthesized (Fig 6a, 0 minutes) . However, average results from three experiments showed that heparin had no effect on the newly synthe- (Fig 7a, lane 1 versus 2) . This change was best illustrated by comparing the 43-kD-to-39-kD ratio before and after SAP treatments. The ratio was 2.2 before treatment with SAP, and it decreased to 0.6 after treatment. The decrease in the ratio was not observed with heat-inactivated SAP or in the presence of phosphatase inhibitors (p-nitrophenyl phosphate and /3-glycerophosphate) (data not shown), indicating that the changes were not due to proteolysis. Similar results were also observed with calf intestine alkaline phosphatase (data not shown). Thus, the conversion of the 39-kD Jun B to the 43-kD Jun B was due to phosphorylation.
Nuclear or cytoplasmic extracts isolated from PMAstimulated SMCs were used as a source of kinases to rephosphorylate SAP-treated 35S-Jun B immunoprecipitates. SAP-treated 5S-Jun B was incubated at 65°C for 15 minutes to inactivate SAP and then phosphorylated with either nuclear or cytoplasmic extracts in the presence of unlabeled ATP. The control was an SAPtreated sample that had not been incubated at 65°C to inactivate SAP before being phosphorylated with nuclear extracts. Rephosphorylation with either nuclear or cytoplasmic extracts caused an increase in the 43-kD Jun B and a decrease in the 39-kD Jun B, as shown by an increase in the 43-kD-to-39-kD ratio from 0.6 to 1.2 and 1.1 (Fig 7a, lane 2 versus 3 and 4) . This change was not observed in the control sample with active SAP during rephosphorylation, as shown by the ratio of 0.7 (Fig 7a, lane 5 ). The sum of the 43-kD and 39-kD Jun B signals was compared between samples treated with and without SAP. The amount recovered from the SAP-treated sample was 87±8% (P= NS, n= 3) of the nontreated sample, indicating that SAP treatment did not cause proteolysis. However, incubation of the SAP-treated 35S-Jun B immunoprecipitates with either nuclear or cytoplasmic extracts resulted in a decrease of the sum of the 43-kD and 39-kD Jun B signals; the amount recovered was 60% of the untreated sample. Although some proteolytic activity was present in the extracts, the increase in the ratio observed in the SAP-treated sample phosphorylated with the extracts (Fig 7a, lane 3 and  4 ) was due to an actual increase in the 43-kD Jun B and a decrease in the 39-kD Jun B. This indicated that the increase in the ratio was not a result of selective proteolytic degradation of the 39-kD Jun B.
In vitro phosphorylation of nuclear extracts isolated from PMA-stimulated SMCs was performed using [y32PJATP. 32P-Jun B in the nuclear extract was recovered by immunoprecipitation using the denaturing condition and then analyzed by SDS-PAGE. Results showed that 32P-Jun B migrated only as the 43-kD band and that no band of 39 kD was detected (Fig 7b) . These observations suggested that the 43-kD band is the phosphorylated form of Jun B at steady state.
The effect of heparin on phosphorylation of Jun B was determined by in vitro phosphorylation of nuclear extracts isolated from PMA+ heparin-treated SMCs. Results showed that the amount of 32P-Jun B (43 kD) recovered from PMA+heparin-treated cells was less than that from PMA-treated cells (Fig 7c) . These results supported the notion that heparin decreases the phosphorylation of Jun B.
Discussion
Heparin inhibits the expression of TPA and collagenase in part by lowering the cellular activity of transcription factor AP-1. 15 In the present study, we examined the effect of heparin on components of AP-1 complexes. The effect of heparin on Jun B expression was both at the transcriptional and posttranscriptional levels. It had a small, but significant, influence in decreasing jun B mRNA induced by PMA, which probably explains the decrease in synthesis of Jun B protein when it was measured with short labeling times. The major effect of heparin was at the level of posttranslational modification of Jun B. Western blot analysis and immunoprecipitates obtained from continuous-labeling experiments detected two species of Jun B, a major band at 43 kD and a minor band at 39 kD. Results from pulse-chase labeling experiments are consistent with the 39-kD Jun B being the precursor and the 43-kD Jun B being the posttranslational modified product in PMA-stimulated cells. The conversion of 39-kD to 43-kD Jun B was suppressed by heparin and seemed to be due to phosphorylation, on the basis of results obtained from both dephosphorylation and rephosphorylation studies. Consistent with these conclusions, it has been shown in 3T3 cells that newly synthesized Jun B is rapidly phosphorylated, resulting in an increase in the apparent molecular weight. 24 In conclusion, we have demonstrated that heparin decreases AP-1 binding in part by decreasing Jun B expression. Heparin probably affects the posttranslational phosphorylation of Jun B. We hypothesize that heparin inhibits the kinases that phosphorylate Jun B. It will be important to identify the kinases that phosphorylate Jun B in vivo, to determine the actual phosphorylation sites in Jun B, and to examine the effect of heparin on phosphorylation of these sites.
